Edwards Lifesciences (NYSE:EW – Get Free Report) posted its quarterly earnings results on Thursday. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67, Briefing.com reports. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the firm earned $0.59 earnings per share. Edwards Lifesciences’s quarterly revenue was up 8.9% on a year-over-year basis.
Edwards Lifesciences Stock Down 1.4 %
EW stock opened at $69.38 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The company has a 50-day moving average of $68.09 and a two-hundred day moving average of $78.39. The stock has a market capitalization of $41.79 billion, a price-to-earnings ratio of 28.55, a price-to-earnings-growth ratio of 3.00 and a beta of 1.13. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $96.12.
Insider Transactions at Edwards Lifesciences
In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,262,521.36. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,250 shares of company stock worth $1,099,238. Company insiders own 1.29% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Recommended Stories
- Five stocks we like better than Edwards Lifesciences
- CD Calculator: Certificate of Deposit Calculator
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is the FTSE 100 index?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How Technical Indicators Can Help You Find Oversold StocksĀ
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.